Menu
Search
|

Menu

Close
X

Rigel Pharmaceuticals Inc RIGL.OQ (NASDAQ Stock Exchange Global Select Market)

2.91 USD
-- (--)
As of Oct 22
chart
Previous Close 2.91
Open --
Volume --
3m Avg Volume 691,496
Today’s High --
Today’s Low --
52 Week High 4.71
52 Week Low 2.56
Shares Outstanding (mil) 124.39
Market Capitalization (mil) 482.64
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.71 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
4
FY16
20
FY15
29
EPS (USD)
FY18
-0.324
FY17
-0.612
FY16
-0.734
FY15
-0.582
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
46.66
5.83
Price to Book (MRQ)
vs sector
6.93
4.89
Price to Cash Flow (TTM)
vs sector
--
22.92
Total Debt to Equity (MRQ)
vs sector
0.00
17.18
LT Debt to Equity (MRQ)
vs sector
0.00
12.76
Return on Investment (TTM)
vs sector
-98.94
14.27
Return on Equity (TTM)
vs sector
-101.42
15.99

EXECUTIVE LEADERSHIP

Raul Rodriguez
President, Chief Executive Officer, Director, Since 2014
Salary: $618,000.00
Bonus: $370,800.00
Dean Schorno
Chief Financial Officer, Executive Vice President, Since 2018
Salary: --
Bonus: --
Dolly Vance
Executive Vice President, Corporate Affairs, General Counsel and Corporate Secretary, Since 2010
Salary: $489,814.00
Bonus: $244,907.00
Anne-Marie Duliege
Executive Vice President- Chief Medical Officer, Since 2016
Salary: $450,000.00
Bonus: $225,000.00
Eldon Mayer
Executive Vice President, Chief Commercial Officer, Since 2016
Salary: $385,000.00
Bonus: $192,500.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

1180 Veterans Blvd
SOUTH SAN FRANCISCO   CA   94080-1985

Phone: +1650.6241100

Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.

SPONSORED STORIES